Ongoing NCI-Funded Clinical Trials Actively Recruiting Patients With Hematologic Cancers: Multiple Myeloma


Get Permission

Study Type: Non-Randomized Phase I/Interventional

Study Title: Multicenter Phase I Study of Th1/Tc1 Immunotherapy Following Autologous Hematopoietic Progenitor Cell Transplantation in High-Risk Multiple Myeloma

Study Sponsor and Collaborators: National Cancer Institute; Hackensack University Medical Center

Purpose: To determine the safety and effectiveness of the infusion of modified Th1 white blood cells, in conjunction with standard treatment, as a treatment for individuals who have been diagnosed with high-risk forms of multiple myeloma.

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Healthy Volunteers: No

Primary Outcome Measures: To evaluate the feasibility and toxicity of an infusion of autologous, ex vivo rapamycin-generated, anti-CD3 and anti-CD28 co-stimulated, Th1/Tc1 lymphocytes in subjects with newly diagnosed high-risk multiple ­myeloma.

Principal Investigator: Daniel H. Fowler, MD, National Cancer ­Institute

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01239368

Study Type: Observational
[Patient Registry]

Study Title: Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis

Study Sponsor and Collaborators: Ohio State University Comprehensive Cancer Center

Purpose: To improve the quality and length of life for patients with diseases of their plasma cells

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Healthy Volunteers: No

Primary Outcome Measures: Develop a data and sample resource that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality of patients diagnosed or living with multiply myeloma in the state of Ohio

Principal Investigator: Craig Hofmeister

 For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01408225


Advertisement

Advertisement



Advertisement